Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
Predicting intraocular inflammation after intravitreous brolucizumab injections
The predictive factors were the previous number of anti-vascular endothelial growth factor and the photometry laser flare-cell (LFCP) value.
Rheumatologic–ophthalmologic teams may be needed to improve management of patients with rheumatic diseases
Austrian investigators advise establishing an interdisciplinary setting, ie, rheumatologic–ophthalmologic, to improve management of patients with rheumatic diseases.
New research data reflect patient satisfaction following faricimab treat-and-extend regimen
A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD.
Subclinical Effects of Anti-VEGF Therapies for Neovascular AMD
The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .
Neuro-ophthalmic adverse events associated with COVID-19 infection and vaccinations
Researchers conducted a large nationwide, population-based, retrospective cohort study to determine if there is an association between COVID-19 infection and vaccination with neuro-ophthalmic adverse events.
Incidence of syphilitic uveitis on the rise in the US
This retrospective, cross-sectional study identified all inpatient diagnosed with syphilitic uveitis in the US between 2010 and 2019.
Novel 3D-printed device may offer a new method to test pharmaceuticals
Moving toward eliminating drug and chemical safety testing in animals
Kingfisher study: Safety and efficacy of brolucizumab for DME
This was a 52-week, double-masked, phase 3 randomized clinical trial in which treatment-naive adults and adults who had previously received anti-VEGF therapy for DME were included.
Tackling visual snow syndrome with mindfulness: Retraining the brain
The investigators use mindfulness-based cognitive therapy (MBCT) on patients who have never previously practiced the technique, with the aim of possibly re-training their brains to remove their static-type images.
Cerebral visual impairment: Documenting the visual effects and simplifying visual life
At first glance, these patients can appear to have normal or near-normal visual
acuity levels. However, in reality, many have perceptual visual deficits, which are not typically tested during a standard ophthalmology office evaluation.
Leveling the playing field when comparing the efficacy of pegcetacoplan and avacincaptad pegol in patients with GA
An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.
Face to face: World’s first whole-eye and partial face transplant
NYU Langone Health performs landmark procedure called “major paradigm shift for potential vision therapies”
AAO 2023: Iveric Bio announces positive Phase 3 results for avacincaptad pegol intravitreal solution for GA secondary to AMD
Patients treated every other month with the drug also showed a similar decrease in the rate of GA progression compared with sham treatment.
Clinical Characteristics and Progression of Geographic Atrophy in a Japanese Population
They believe that these phenotypic differences in GA should be considered in different ethnicities because they may have implications in research and in interventions to slow progression of GA.
AAO 2023: Pediatric macular holes: Causes, characteristics, and care
Researchers found that spontaneous macular hole closure and surgical treatment seem to be associated with comparable rates of closure and visual outcomes.
AAO 2023: Cost-effectiveness analysis of pegcetacoplan for treating GA
The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.
AAO 2023: OCT and OCTA longitudinal study further highlights macular thickness and microvascular changes in children with sickle cell disease
OCT and OCTA imaging were especially valuable in this patient population because the images extended the current definition of sickle cell retinopathy.
AAO 2023: TWO-ROP algorithm: Simplifying the screening process
Investigators have proposed a new algorithm, TWO-ROP, which they describe as “a new and simple screening protocol with a two-tiered impatient and outpatient approach.”
Ocular evaluations recommended for patients with primary vasculitis
Researchers underscored the importance of ocular examinations in patients with primary vasculitis, defined as without an apparent cause.
Johnson & Johnson Vision focuses on barriers faced by women in ophthalmology
Identifying and surmounting gender barriers in ophthalmology.
AAO 2023: San Francisco: Where All of Ophthalmology Meets®
The American Academy of Ophthalmology (AAO) 2023 annual meeting is returning home to San Francisco on Friday November 3 through Monday November 6.
Pegcetacoplan injections for geographic atrophy associated with silicone oil drops in vitreous cavity
The use of silicone-free syringes advised with these drops.
Retina Society 2023: Experimental study of evaporative heavy liquids for retinal tamponade
The investigators performed clinical examinations and obtained fundus photographs and inferior optical coherence tomography (OCT) images for both treatments at baseline and on days 1, 3, 8, 15, and 56 after the injections.
Retina Society 2023: A modified endolaser instrument for chandelier scleral buckle procedures
A modified endolaser setup was found to be safe and efficient for use during chandelier scleral buckling.
Retina Society 2023: Association between geographic atrophy and meaningful disease burden over time
Visual acuity changes and conversion to neovascular AMD determined over 3 years in large patient cohort.
Potential bacterial involvement in the development of severe ROP
Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.
World Sight Day 2023: Focusing on preservation of vision in the workplace
World Sight Day on October 12 highlights the vital role of eye care in workplaces. The International Agency for the Prevention of Blindness urges employers to prioritize eye health, aiming to enhance well-being, safety, and productivity.
Aflibercept 8 mg for DME Dosed Every 12/16 Weeks: Comparable BCVA to Every-8-Week Dosing
Few injections lowers treatment burden and maintains safety profile.
Phase 3 PULSAR Study: Aflibercept 8 mg Monotherapy for PCV: Robust Efficacy Benefits
A subgroup analysis of the phase 3 PULSAR Trial showed robust increases in the best-corrected visual acuity (BCVA) compared with baseline at week 48.
LEAD Study: Reducing AMD Progression Rates with Subthresold Nanosecond Laser in Eyes with No Pseudo-Drusen
Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual Euretina Congress, Amsterdam.
2 Clarke Drive Cranbury, NJ 08512